Endo Pharmaceuticals to buy Qualitest
The privately held generics company will sell for about $1.2 billion in cash.
By Andrea Tse, TheStreet
Endo Pharmaceuticals (ENDP) said Tuesday it will buy privately held U.S. generics company Qualitest Pharmaceuticals for about $1.2 billion in cash.
Endo said it intends to finance the purchase using $500 million in cash from its balance sheet, plus an existing $300 million revolving credit facility. The company also said it has secured financing for up to $400 million. The transaction is expected to close late in the fourth quarter or early in the first quarter of 2011.
The company expects the transaction to immediately add to earnings in the first full year after the close. After the deal closes, Endo anticipates Qualitest will add about $400 million in annualized revenue and 40 cents in annualized adjusted earnings per share.
Endo also expects revenue growth of the combined generics business to be at least 15% over the next two years. The company expects to realize a $30 million annualized cost synergy run-rate in 2013.
Pro forma for fiscal 2010, the combined company would have had revenue of about $2 billion and more than 3,000 employees, Endo said.
Endo said Qualitest is the sixth-largest U.S. generics company, as measured by prescriptions filled.
Endo reiterated its 2010 revenue guidance of between $1.63 billion and $1.68 billion and full-year adjusted earnings per share of between $3.30 and $3.35. Analysts, on average, expect full-year earnings of $3.35 a share on revenue of $1.67 billion.
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
[BRIEFING.COM] The major averages ended modestly lower with the S&P 500 shedding 0.3%.
The benchmark average saw an opening loss of 1.2% after Japan's Nikkei tumbled 7.3%. Japanese stocks sold off amid continued volatility in Japanese Government Bond futures as the 10-yr yield spiked almost 16 basis points to 1.002 before the Bank of Japan's JPY2 trillion liquidity injection caused yields to retrace their gains.
Adding insult to injury was news out of China where the HSBC ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|
LATEST MARKET DISPATCHES
- No more Dispatches; here's where to find market news
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
- Dow falls 59 as late-day gloom kills a rally
- Stocks held back by fiscal-cliff worries
- Stocks suffer worst weekly loss in 5 months
- Dow off 121 as post-election swoon continues
- Dow slumps 313 after Obama's re-election
- Dow jumps 133 as Americans head to the polls
In the never-ending contest for sales, American carmakers are pulling ahead.